Sarepta: Barclays Keeps Overweight Rating, Raises PT to $32 from $29.

Sarepta: Barclays Keeps Overweight Rating, Raises PT to $32 from $29.

In a significant move, analysts at Barclays have raised their price target for Sarepta Therapeutics (NASDAQ: SRPT) from $29.00 to $32.00, reflecting a potential upside of 44.79% from the stock's previous close [1]. The firm maintains an "overweight" rating on the biotechnology company's stock, suggesting a positive outlook on its future performance.

Sarepta Therapeutics has been the subject of various research reports, with analysts adjusting their price targets and ratings. Jefferies Financial Group lowered their price target from $125.00 to $54.00 and set a "buy" rating, while Guggenheim reduced their price objective from $112.00 to $98.00 with a "buy" rating [1]. Cantor Fitzgerald maintained a "neutral" rating, and Robert W. Baird raised their price objective from $30.00 to $35.00 with an "outperform" rating [1]. Oppenheimer lowered their price objective from $123.00 to $45.00 with an "outperform" rating [1]. Despite these mixed signals, the average analyst rating is "Hold" with a consensus price target of $57.42 [1].

The stock has experienced significant volatility, trading up $3.72 to $22.10 on Thursday, July 17, 2025 [1]. The company's financial health is indicated by a current ratio of 4.02, a quick ratio of 2.46, and a debt-to-equity ratio of 1.00 [1]. Institutional investors have been active in the stock, with various firms acquiring or increasing their stakes in the first quarter [1].

Sarepta Therapeutics' restructuring plan, announced in July 2025, aims to align its resources with high-impact therapies while addressing financial pressures [2]. The company's strategic pivot includes a $400 million annual cost-savings initiative, which will reduce non-GAAP R&D and SG&A expenses to $800–$900 million by 2026. This restructuring is crucial for meeting 2027 debt obligations and retaining flexibility for strategic initiatives [2].

The company's Q2 2025 revenue stability in Duchenne muscular dystrophy (DMD) franchise, which generated $513 million in net product revenue, underscores its resilience [2]. ELEVIDYS, the company's gene therapy, contributed $282 million, while RNA-based PMOs added $231 million. The FDA's demand for a black box warning on ELEVIDYS has tempered enthusiasm, but Sarepta is proactive in addressing this issue [2].

Sarepta's pivot to its siRNA platform is a key strategic move, with programs targeting FSHD, DM1, SCA2, and Huntington's disease advancing [2]. The company aims to deliver near-term milestones, such as Phase 3 trial readouts and Phase 2 trial data, which could accelerate clinical development and reduce costs [2].

Investors must weigh Sarepta's strategic merits against risks, including execution risks in complex diseases, regulatory hurdles, and market competition [2]. Despite these challenges, Sarepta's strategic pivot and robust Q2 performance position it as a compelling investment in the rare genetic disease space.

References:
[1] https://www.marketbeat.com/instant-alerts/sarepta-therapeutics-nasdaqsrpt-price-target-raised-to-3200-2025-07-17/
[2] https://www.ainvest.com/news/sarepta-therapeutics-restructures-profitability-strategic-pivot-rare-genetic-therapies-2507/